{"id":"diazoxide-choline-controlled-release-tablet","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypotension"},{"rate":"5-10%","effect":"Tachycardia"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4297276","moleculeType":"Small molecule","molecularWeight":"333.84"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Diazoxide acts by blocking ATP-sensitive potassium channels, leading to vasodilation and increased blood pressure.","oneSentence":"Potassium channel blocker","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:32:42.441Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT03714373","phase":"PHASE3","title":"Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period","status":"COMPLETED","sponsor":"Soleno Therapeutics, Inc.","startDate":"2018-10-01","conditions":"Prader-Willi Syndrome","enrollment":115},{"nctId":"NCT03440814","phase":"PHASE3","title":"A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome","status":"COMPLETED","sponsor":"Soleno Therapeutics, Inc.","startDate":"2018-05-09","conditions":"Prader-Willi Syndrome","enrollment":127},{"nctId":"NCT04086810","phase":"PHASE3","title":"An Open-Label Study of DCCR Tablet in Patients With PWS","status":"WITHDRAWN","sponsor":"Soleno Therapeutics, Inc.","startDate":"2019-10","conditions":"Prader-Willi Syndrome","enrollment":""},{"nctId":"NCT02893618","phase":"PHASE2","title":"A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)","status":"UNKNOWN","sponsor":"Essentialis, Inc.","startDate":"2017-07","conditions":"Prader-Willi Syndrome","enrollment":32},{"nctId":"NCT00973271","phase":"PHASE3","title":"Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides","status":"WITHDRAWN","sponsor":"Essentialis, Inc.","startDate":"2011-03","conditions":"Hypertriglyceridemia","enrollment":""},{"nctId":"NCT02034071","phase":"PHASE1, PHASE2","title":"Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome","status":"COMPLETED","sponsor":"Essentialis, Inc.","startDate":"2014-04","conditions":"Prader-Willi Syndrome","enrollment":13},{"nctId":"NCT00901823","phase":"PHASE1","title":"Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide Choline","status":"WITHDRAWN","sponsor":"Essentialis, Inc.","startDate":"2011-03","conditions":"Hypertriglyceridemia","enrollment":""},{"nctId":"NCT01211847","phase":"PHASE2","title":"Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia","status":"COMPLETED","sponsor":"Essentialis, Inc.","startDate":"2010-10","conditions":"Hypertriglyceridemia, Dyslipidemia","enrollment":44},{"nctId":"NCT01211860","phase":"PHASE1","title":"Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects","status":"COMPLETED","sponsor":"Essentialis, Inc.","startDate":"2010-10","conditions":"Hypertriglyceridmia","enrollment":9},{"nctId":"NCT00688857","phase":"PHASE1","title":"Open-label Pharmacokinetic Study of Diazoxide Choline Coated vs. Uncoated Formulations","status":"COMPLETED","sponsor":"Essentialis, Inc.","startDate":"2008-05","conditions":"Hypertriglyceridemia","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DCCR"],"phase":"phase_2","status":"active","brandName":"Diazoxide Choline Controlled-Release Tablet","genericName":"Diazoxide Choline Controlled-Release Tablet","companyName":"Essentialis, Inc.","companyId":"essentialis-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Potassium channel blocker Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}